Streetbeat News

Price Targets

HWC

Stephens & Co. analyst Matt Olney has maintained an Equal-Weight rating on Hancock Whitney (NASDAQ:HWC) but has reduced the price target from $55 to $50.

Portfolio Pulse from Benzinga Newsdesk

January 17, 2024 | 1:36 pm

KNTE

Wedbush analyst David Nierengarten has reiterated a Neutral rating on Kinnate Biopharma (NASDAQ:KNTE) and maintained a price target of $2.

Portfolio Pulse from Benzinga Newsdesk

January 17, 2024 | 1:32 pm

FANG

Diamondback Energy Inc. (NASDAQ:FANG) shares are trading at $150.40 with a recent 0.50% decrease. Over the past month, FANG's stock has dropped by 3.48%, but it has increased by 2.71% over the past year. The company's P/E ratio is lower than the industry average, which could suggest that the stock is undervalued or that shareholders have low growth expectations. Investors are advised to consider the P/E ratio alongside other financial metrics and qualitative analysis for investment decisions.

Portfolio Pulse from Benzinga Insights

January 17, 2024 | 1:30 pm

RCUS

Wedbush analyst Robert Driscoll has reiterated an Outperform rating on Arcus Biosciences (NYSE:RCUS) and maintained a price target of $36. This reaffirmation of the stock's potential could influence investor sentiment and stock performance in the short term.

Portfolio Pulse from Benzinga Newsdesk

January 17, 2024 | 1:24 pm

SKX

Wedbush analyst Tom Nikic has maintained an Outperform rating on Skechers USA (NYSE:SKX) and increased the price target from $62 to $75, indicating a positive outlook on the company's stock.

Portfolio Pulse from Benzinga Newsdesk

January 17, 2024 | 1:22 pm

KMX

Wedbush analyst Seth Basham has reiterated an Outperform rating on CarMax (NYSE:KMX) and maintained a price target of $90.

Portfolio Pulse from Benzinga Newsdesk

January 17, 2024 | 1:20 pm

ALLK

ANSS

APLS

BURL

MS

NFLX

SEDG

TWST

VC

WALD

Wall Street analysts have updated their price targets and ratings for several US-listed companies. Keybanc raised Netflix's target to $545, maintaining an Overweight rating. Goldman Sachs increased Twist Bioscience's target to $45 and upgraded it to Buy. Piper Sandler raised Burlington Stores' target to $240 and upgraded to Overweight. UBS increased Visteon's target to $145 and upgraded to Buy. JP Morgan lowered Morgan Stanley's target to $87 and downgraded to Neutral. Rosenblatt raised ANSYS's target to $345 but downgraded to Neutral. Barclays cut SolarEdge's target to $50 and downgraded to Underweight. HC Wainwright raised Apellis Pharmaceuticals' target to $92, maintaining a Buy rating. Telsey Advisory cut Waldencast's target to $12 but kept an Outperform rating. Jefferies slashed Allakos's target to $1.5 and downgraded to Hold.

Portfolio Pulse from Avi Kapoor

January 17, 2024 | 1:19 pm

PYPL

PayPal Holdings Inc (NASDAQ:PYPL) saw its shares decline after Mizuho downgraded the stock from Buy to Neutral and lowered the price target from $72 to $65. BofA Global Research is looking forward to PayPal's Q4 results and 2024 guidance from new leadership, maintaining a Neutral rating with a $66 price objective. Analysts expect a year-over-year decline in transaction profit growth but at a slower rate than Q3. The stock is expected to be range-bound in the short term due to valuation concerns and weak sentiment.

Portfolio Pulse from Surbhi Jain

January 17, 2024 | 1:17 pm

RKLB

Keybanc analyst Michael Leshock has initiated coverage on Rocket Lab USA (NASDAQ:RKLB) with an Overweight rating and set a price target of $8 for the company's stock.

Portfolio Pulse from Benzinga Newsdesk

January 17, 2024 | 1:15 pm

TASK

TaskUs (NASDAQ:TASK) received mixed analyst ratings with an updated average 12-month price target of $13.25, reflecting an 8.16% increase from the previous target. Citigroup and JP Morgan raised their price targets, while Morgan Stanley lowered theirs. TaskUs's financials show a market cap below industry average, a -2.8% revenue decline, but strong net margin, ROE, and ROA. The company's debt-to-equity ratio is also below industry average.

Portfolio Pulse from Benzinga Insights

January 17, 2024 | 1:01 pm